<DOC>
	<DOCNO>NCT01743651</DOCNO>
	<brief_summary>This multicenter , randomize ( 1:1:1 ) , double-blind , active placebo control , parallel group study evaluate safety , tolerability efficacy oral arbaclofen MS patient spasticity . Eligible subject remove anti-spasticity mediation least one week begin study drug treatment daily dose increase target dose maintain least 12 week . A down-titration occur two week final study visit occur 19 week start achieve target dose 22 week Study Visit 1 .</brief_summary>
	<brief_title>Efficacy Study Arbaclofen Treat Spasticity Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Muscle Spasticity</mesh_term>
	<criteria>Patients ( male female ) 18 65 year age , inclusive , time dose Have establish diagnosis ( per McDonald Criteria ) Multiple Sclerosis ( either relapse remit secondary progressive course ) , manifest spasticity least 6 month Spasticity due MS show TNmAS score equal great six ( ≥6 ) affect limb . EDSS equal great 3.0 If receive diseasemodifying medication , must stable dose least three ( 3 ) month prior screen , subject must willing maintain treatment duration study Stable regimen least thirty ( 30 ) day prior study entry medication nonpharmacological therapy intend alleviate spasticity Absence infection , peripheral vascular disease , painful contracture , advance arthritis , condition hinder evaluation joint movement Have creatinine clearance , calculate Glomerular Filtration Rate use Modification Diet Renal Disease ( MDRD ) Study equation , great 60mL/min . Use medically highly effective birth control study ninety ( 90 ) day thereafter woman childbearing potential ( include female subject female partner nonsterile male subject ) Willing allow general practitioner consultant , appropriate , notified participation study Any concomitant disease disorder symptom spasticity may influence subject 's level spasticity Inability rate level spasticity distinguish MS symptom Acute MS exacerbation require treatment within twelve ( 12 ) week screen Use intravenous methylprednisolone within twelve ( 12 ) week visit 1 Concomitant use medication would potentially interfere action study medication outcome variable Use botulinum toxin A B within six ( 6 ) month visit 1 History allergy baclofen inactive component test reference formulation Pregnancy , lactation plan pregnancy course study three ( 3 ) month thereafter . History unstable psychiatric disease , current sign symptom significant medical disorder severe , progressive , uncontrolled pulmonary , cardiac , gastrointestinal , hepatic , renal , genitourinary , hematological , endocrine , immunologic , neurological disease History seizures Current significant cognitive deficit , severe untreated anxiety , severe untreated depression Subjects abnormal micturition require indwell intermittent catheterization lower urinary tract symptom ( LUTS ) result score great twentysix ( &gt; 26 ) Baseline USP© questionnaire Current malignancy history malignancy remission five ( 5 ) year , except effectively treat basal cell skin carcinoma Any significant disease , disorder significant laboratory finding , opinion investigator , put subject risk participation , influence result study , affect subject 's ability participate Planned elective surgery procedure require general anesthesia study Subject inappropriate placebo medication judgment Investigator History substance abuse within past twelve ( 12 ) month Current chronic use long acting opioids round clock use short act opioids treatment pain Participation another research study within thirty ( 30 ) day Screening Patients uncooperative unwilling sign consent form</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>spasticity</keyword>
	<keyword>multiple sclerosis</keyword>
	<keyword>arbaclofen</keyword>
</DOC>